2024-11-20 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis Report

**1. Performance Comparison and Divergence:**

Johnson & Johnson (JNJ), a diversified healthcare company,  has significantly underperformed the S&P 500 (VOO) over the analyzed period. While JNJ shows a cumulative return of 35.7%, VOO boasts a return of 124.78%. This results in a substantial negative divergence of -89.08%.  The relative divergence of 4.67% indicates that JNJ's performance sits near the lower end of its historical performance range relative to the S&P 500.  The provided CAGR data shows varying performance over different time periods, ranging from a high of 45.2% to a low of -2.4%, highlighting the volatility of returns.  The Maximum Drawdown (MDD) values also point to significant periods of losses.  The Beta consistently below 1 indicates lower volatility compared to the market.  However, Alpha values consistently above 0 highlight the added value JNJ provides above the market.

**2. Recent Price Movement:**

* **Closing Price:** $154.77 (Last Market: $152.6)
* **5-day Moving Average:** $153.3
* **20-day Moving Average:** $158.22
* **60-day Moving Average:** $161.77

The stock price is currently below its 5, 20, and 60-day moving averages, suggesting a downtrend.  The relatively small difference between the closing price and the last market price indicates relatively stable trading in the short term.

**3. Technical Indicators and Expected Return:**

* **RSI (31.16):**  Indicates the stock is in oversold territory, suggesting potential for a bounce.
* **PPO (-0.29):**  Negative value suggests bearish momentum.
* **Recent Relative Divergence (-1.45):** Shows a short-term decline relative to the S&P 500.

The combination of a low RSI and negative PPO, coupled with a negative recent relative divergence and the price being below its moving averages, points towards a bearish short-term outlook.  The expected return is listed as 0.0%, indicating no expectation of outperformance over the S&P 500 in the short term, although a long-term (2+ years) buy-and-hold strategy *might* yield a positive alpha, considering historical performance. However, this long-term projection is uncertain and contingent on various market factors.  The provided data does not reflect any recent sharp price movements (sudden jumps or drops).

**4. Recent Earnings and Outlook:**

The provided earnings data shows some fluctuations in EPS and revenue. While revenue remains relatively consistent, EPS is volatile.  The most recent EPS of 1.12 falls below the preceding quarters.  To properly assess the most recent earnings, a comparison with analyst expectations (which are missing from the provided data) is necessary.  Without this information, a definitive conclusion about the latest earnings is impossible.


**5. Financial Information:**

* **Revenue and Profitability:** Shows consistently high profit margins (around 69%) over the past several quarters, indicating strong profitability.  Revenue has remained relatively stable.
* **Capital and Profitability:** Equity and ROE show some volatility.  The exceptionally high ROE in 2023-09-30 warrants further investigation to understand the contributing factors.

The financial data suggests a generally healthy financial position but necessitates a deeper dive into specific drivers of the observed variability.

**6. News and Recent Issues:**

(This section requires access to real-time news sources.  Please provide recent news articles or reports for a complete analysis.  I can then analyze the information presented regarding recent earnings announcements, analyst opinions, and market outlook for JNJ).

**7. Comprehensive Analysis:**

JNJ has shown a consistent, but not remarkable, track record of profitability. While the company demonstrates strong financial fundamentals in terms of profit margins and revenue, its stock performance has lagged significantly behind the S&P 500 in recent periods. Technical indicators suggest a potentially oversold condition, but the bearish momentum and negative relative divergence are important considerations.  A thorough examination of the most recent earnings announcement, incorporating analyst expectations and any recent news or market developments, is crucial for a complete investment decision.  The long-term outlook depends heavily on the sustained strength of the healthcare industry and JNJ's ability to navigate regulatory changes and competitive pressures.

**8. Conclusion:**

The data suggests a mixed outlook for JNJ. While the company exhibits solid financial health and historically strong profitability, its recent underperformance relative to the broader market and the present bearish technical indicators raise concerns. A detailed analysis of recent earnings compared to expectations, along with up-to-date news and analyst opinions, is essential before forming a well-informed investment decision.  The inherent risk in any investment, particularly in light of the current market environment, should be carefully considered.
